BiotechTube

Ceftolozane-Tazobactam + Meropenem

ApprovedRecruiting
1 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Febrile Neutropenia

Conditions

Febrile Neutropenia

Trial Timeline

Mar 26, 2025 → Dec 1, 2026

NCT ID
NCT06342115

About Ceftolozane-Tazobactam + Meropenem

Ceftolozane-Tazobactam + Meropenem is a approved stage product being developed by Merck for Febrile Neutropenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06342115. Target conditions include Febrile Neutropenia.

What happened to similar drugs?

3 of 7 similar drugs in Febrile Neutropenia were approved

Approved (3) Terminated (4) Active (2)
✅Imipenem + ImipenemMerckApproved
✅Ceftolozane-tazobactam IVMerckApproved
✅Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)Gilead SciencesApproved
❌HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
❌Daptomycin + DaptomycinMerckPhase 3
🔄linezolid + vancomycinPfizerPhase 3
🔄ciprofloxacin + cefepimeBayerPhase 3

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06342115ApprovedRecruiting
NCT04238390Phase 3Withdrawn

Competing Products

8 competing products in Febrile Neutropenia

See all competitors
ProductCompanyStageHype Score
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
32
Imipenem + ImipenemMerckApproved
43
Ceftolozane-tazobactam IVMerckApproved
35
Daptomycin + DaptomycinMerckPhase 3
32
Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)Gilead SciencesApproved
35
linezolid + vancomycinPfizerPhase 3
40
Antibacterial agent for the treatment of febrile neutropeniaPfizerPre-clinical
26
ciprofloxacin + cefepimeBayerPhase 3
37